Apr 15
|
Transactions in Connection with Share Buy-back Program Genmab
|
Feb 27
|
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
|
Feb 27
|
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
|
Feb 26
|
Transactions in connection with share buy-back program
|
Feb 23
|
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
|
Jan 9
|
GMAB or TECH: Which Is the Better Value Stock Right Now?
|
Jan 9
|
TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer
|
Jan 9
|
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
|
Jan 2
|
Genmab to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
Dec 9
|
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
|
Dec 9
|
New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
|
Dec 7
|
HRMY or GMAB: Which Is the Better Value Stock Right Now?
|
Dec 5
|
Capital Increase in Genmab as a Result of Employee Warrant Exercise
|
Nov 28
|
AbbVie (ABBV) Lymphoma Drug Gets FDA Breakthrough Therapy Tag
|
Nov 27
|
Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma
|
Sep 28
|
Grant of Restricted Stock Units and Warrants to Employees in Genmab
|
Sep 28
|
Diversified Stock Portfolio: 10 Sector ETFs and International ETFs to Buy
|